Tolga ÇİMEN, Ekrem YETER, Mehmet DOĞAN, Murat AKÇAY, HÜSEYİN AYHAN, Telat KELEŞ, Tahir DURMAZ, Nihal Akar BAYRAM, Engin BOZKURT

Decreased hepcidin-25 level as a predictor of poor prognosis in acute coronary syndrome patients

Akut koroner sendromlu hastalarda kötü prognoz göstergesi olarak azalmıştır Hepsidin-25 Düzeyi

Background: The peptide hormone hepcidin-25 is known as a type-II acute phase protein in patients with chronic inflammatory conditions and it has a central role in iron homeostasis as well as in anemia, inflammation and hypoxia. Atherosclerosis is widely accepted as a chronic inflammatory disease. Herein, we evaluated whether hepcidin-25 level has a prognostic role in patients with acute coronary syndromes (ACS). Material and Method: Forty-eight patients with ACS admitted to the coronary care unit of our hospital were included in Group 1, 19 patients without any significant coronary artery disease were included in Group 2 and 20 healthy subjects as control were included in Group 3. Serum hepcidin-25 levels were measured with Hepcidin ELISA kits. Results: Patients with ACS were followed-up for up to 24 months after admission with regard to cardiac events including death, myocardial infarction and revascularisa- tion. There was no significant difference between the baseline biochemical and clinical characteristics of Group 1 and Group 2. Hepcidin-25 level was lower in Group 1 when compared with other Groups (192± 74 ng/mL, 296 ±104 ng/mL, 303.8±92.1, p<0.01). Hepcidin-25 level was found significantly lower in patients who developed a cardiac event compared to those who did not (140 ± 78 ng/ml vs 208±74 ng/ml, p<0.05) but ferritin and hsCRP were similar. Conclusions . Reduced serum hepcidin-25 levels might predict poor outcome in patients with ACS.

PDF

___

1. Ramakrishna G, Rooke TW, Cooper LT. Iron and peripheral arterial disease: revisiting the iron hypothesis in a different light. Vasc Med 2003;8(3):203-10.

2. Turoczi T, Jun L, Cordis G, Morris JE, Maulik N, Stevens RG, et al. HFE mutation and dietary iron content interact to increase ischemia/ reperfusion injury of the heart in mice. Circ Res 2003;92(11):1240-6.

3. Oudit GY, Trivieri MG, Khaper N, Husain T, Wilson GJ, Liu P, et al. Taurine supplementation reduces oxidative stress and improves cardiovascular function in an iron-overload murine model. Circulation 2004;109(15):1877-85.

4. Krause A, Neitz S, Mägert HJ, Schulz A, Forssmann WG, Schulz- Knappe P, et al. LEAP-1, a novel highly disulfide-bounded human peptide, exhibits antimicrobial activity. FEBS Lett 2000;480(2-3):147-50.

5. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 2001;276(11): 7806-10.

6. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 2002;110(7):1037-44.

7. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 2001;276(11):7811-9.

8. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306(5704):2090-3.

9. Lee P, Peng H, Gelbart T, Beutler E. The IL-6- and lipopolysaccharide-induced transcription of hepcidin in HFE-, transferrin receptor 2-, and beta 2-microglobulin-deficient hepatocytes. Proc Natl Acad Sci U S A 2004;101(25):9263-5.

10. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute- phase protein. Blood 2003;101(7):2461-3.

11. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003;102(3):783-8.

12. Suzuki H, Toba K, Kato K, Ozawa T, Tomosugi N, Higuchi M, et al. Serum hepcidin-20 is elevated during the acute phase of myocardial infarction. Tohoku J Exp Med 2009;218(2):93-8.

13. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST- elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol 2004;44(3):671-719.

14. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007;50(7):e1-e157.

15. Merle U, Fein E, Gehrke SG, Stremmel W, Kulaksiz H. The iron regulatory peptide hepcidin is expressed in the heart and regulated by hypoxia and inflammation. Endocrinology 2007;148(6):2663-8.

16. Fluck DC, Valentine PA, Treister B, Higgs B, Reid DN, Steiner RE. Right heart pressures in acute myocardial infarction. Br Heart J 1967;29(5):748-57.

17. Valencia A, Burgess JH. Arterial hypoxemia following acute myocardial infarction. Circulation 1969;40(5):641-52.

18. Valentine PA, Fluck DC, Mounsey JP, Reid D, Shillingford JP, Steiner RE. Blood-gas changes after acute myocardial infarction. Lancet 1966;2(7468):837-41.

19. Muir AL, Kirby BJ, King AJ, Miller HC. Mixed venous oxygen saturation in relation to cardiac output in myocardial infarction. Br Med J 1970;4(5730):276-8.

20. Ljungstrom B, Johansson BW, Sievers J. Arterial pO2, pCO2, pH and standard bicarbonate in patients with an acute myocardial infarction. Cardiologia 1967;51(3):138-47.

21. Sukumalchantra Y, Danzig R, Levy SE, Swan HJ. The mechanism of arterial hypoxemia in acute myocardial infarction. Circulation 1970;41(4):641-50.

22. Sukumalchantra Y, Levy S, Danzig R, Rubins S, Alpern H, Swan HJ. Correcting arterial hypoxemia by oxygen therapy in patients with acute myocardial infarction. Effect on ventilation and hemodynamics. Am J Cardiol 1969;24(6):838-52.

23. Finley TN, Swenson EW, Comroe JH. The cause of arterial hypoxemia at rest in patients with "alveolarcapillary block syndrome". J Clin Invest 1962;41:618-22.

24. Maruna P, Lindner J, Kunstýr J, Plocová K, Hubácek J. Plasma prohepcidin as a negative acute phase reactant after large cardiac surgery with a deep hypothermic circulatory arrest. Physiol Res 2008.

25. Oguz A, Uzunlulu M, Hekim N. Hepcidin is not a marker of chronic inflammation in atherosclerosis. Anadolu Kardiyol Derg 2006;6(3):239-42.

26. Kemna E, Pickkers P, Nemeth E, van der Hoeven H, Swinkels D. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood 2005;106(5):1864-6.

27. Murphy AT, Witcher DR, Luan P, Wroblewski VJ. Quantitation of hepcidin from human and mouse serum using liquid chromatography tandem mass spectrometry. Blood 2007;110(3):1048-54.

28. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340(2):115-26.

29.Torguoglu EI, Gurgun C, Zoghi M, Türkoğlu C.The relationship between serum C-reactive protein levels and coronary artery disease in patients with stable angina pectoris and positive exercise stress test. Anadolu Kardiyol Derg 2004;4(3):199-202.